Visium Asset Management’s Filana Therapeutics FLNA Stock Holding History

Visium Asset Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-621,429	Closed	-$8.22M	–	1272
2015 Q1	$8.22M	Sell	621,429 -7	-0%	-$94	0.12%	174
2014 Q4	$8.83M	Sell	621,436 -7	-0%	-$121	0.12%	149
2014 Q3	$17M	Buy	621,443 +14	+0%	+$425	0.25%	85
2014 Q2	$25M	Hold	621,429	–	–	0.39%	44
2014 Q1	$23.9M	Hold	621,429	–	–	0.39%	53
2013 Q4	$21.1M	Hold	621,429	–	–	0.42%	50
2013 Q3	$11.8M	Hold	621,429	–	–	0.27%	71
2013 Q2	$9.61M	Buy	+621,429	New	+$13.1M	0.22%	81

Other funds holding FLNA

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Visium Asset Management's FLNA Position: Q2 2015 in Review

Visium Asset Management sold out of Filana Therapeutics (FLNA) in Q2 2015, closing a stake of 621,429 shares — an estimated $8.22M sold.

Visium Asset Management first reported a position in FLNA in Q2 2013 and held it in 8 quarters. The position peaked at $25M in Q2 2014. 66 funds tracked by Wall St. Rank hold FLNA as of Q2 2015.

Visium Asset Management reported no remaining Filana Therapeutics position as of Q2 2015 after selling out during the quarter.
Visium Asset Management sold 621,429 Filana Therapeutics shares in Q2 2015, an estimated $8.22M.
Visium Asset Management first reported a position in Filana Therapeutics in Q2 2013 and held it in 8 quarters.
Visium Asset Management's Filana Therapeutics position peaked at $25M in Q2 2014.
66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2015.

Based on Visium Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.